Opportunities for enhancing the FDA guidance on pharmacovigilance

JAMA

Volumn 300, Issue 8, 2008, Pages 952-954

  Psaty, Bruce M ^a,b   Vandenbroucke, Jan P ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

CARDIOVASCULAR RISK; DRUG APPROVAL; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART INFARCTION; HUMAN; NOTE; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; SIDE EFFECT; ARTICLE; CLINICAL TRIAL; OBSERVATION; RANDOMIZED CONTROLLED TRIAL; SAFETY; UNITED STATES;

CLINICAL TRIALS AS TOPIC; CONSUMER PRODUCT SAFETY; OBSERVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 50549098780     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.8.952     Document Type: Note

References (15)

1. Food and Drug Administration. Developing guidance on conducting scientifically sound pharmacoepidemiologic safety studies using large electronic healthcare data sets: public workshop: request for comments. Fed Regist. 2008;73(79):21963-21964.
2. Food and Drug Administration. The Sentinel Initiative: national strategy for monitoring medical product safety. http://www.fda.gov/oc/initiatives/ advance/reports/report0508.pdf. Accessed July 17, 2008.
3. Misbin RI. Medical office review of Avandia: application number: 021071: Center for Drug Evaluation and Research. http://oversight.house.gov/story.asp? ID=1325. Accessed July 17, 2008.
4. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
5. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-1105.
6. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) Study: interim findings on cardiovascular hospitalizations and deaths. N Engl J Med. 2007;357(1):28-38.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2472.
8. Vandenbroucke J. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5:e67; supplemental material. http://medicine.plosjournals.org/archive/1549-1676/5/3/supinfo/10.1371_journal. pmed.0050067.sd001.pdf.
9. Joffe HV, Parks M, Meyer R, Jenkins J, Temple R. Rosiglitazone and the FDA. N Engl J Med. 2007;357(17):1775-1776.
10. Psaty BM, Ray W. FDA guidance on off-label promotion and the state of the literature from sponsors. JAMA. 2008;299(16):1949-1951.
11. Food and Drug Administration Amendments Act of 2007. HR 3580, enacted by the House and Senate, Pub L No. 110-85. http://frwebgate.access.gpo.gov/cgi-bin/ getdoc.cgi?dbname=110_cong_bills&docid=f:h3580enr.txt.pdf. Accessed October 11, 2007.
12. von Elm E, Altman D, Egger M, Pocock S, Götzsche P, Vandenbroucke J. STROBE Initiative: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577.
13. Rossouw JE; Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
15. Gerstein HC; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.